Patents Assigned to OVID THERAPEUTICS INC
  • Methods of increasing tonic inhibition and treating secondary insomnia
    Patent number: 9801864
    Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 31, 2017
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Methods of treatment Rett syndrome
    Patent number: 9744159
    Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 29, 2017
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Methods of sedation during critical care treatment
    Patent number: 9717716
    Abstract: Methods of sedating a patient undergoing critical care treatment using intravenous gaboxadol are provided.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: August 1, 2017
    Assignee: OVID THERAPEUTICS INC
    Inventors: Matthew During, Anna Kazanchyan
  • Methods of treating Dravet syndrome
    Patent number: 9682069
    Abstract: Methods of treating a developmental disorder such as Dravet syndrome by administering a pharmaceutical composition of gaboxadol or a pharmaceutically acceptable salt thereof are provided.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 20, 2017
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Methods of treating Prader-Willi Syndrome
    Patent number: 9610261
    Abstract: Methods of treating Prader-Willi syndrome in a subject in need of treatment are provided. The methods include administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R, R?, X, Y and Z are defined as set forth in the specification. In embodiments, an effective amount of captodiamine or a pharmaceutically acceptable salt thereof is administered to the subject.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 4, 2017
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome
    Patent number: 9446028
    Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: September 20, 2016
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Methods of sedation during critical care treatment
    Patent number: 9399034
    Abstract: Methods of sedating a patient undergoing critical care treatment using intravenous gaboxadol are provided.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: July 26, 2016
    Assignee: OVID THERAPEUTICS INC
    Inventors: Matthew During, Anna Kazanchyan
  • Methods of treating developmental disorders using pipradrol
    Patent number: 9351968
    Abstract: Methods of treating developmental disorders by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat conditions such as epilepsy, Landau-Kleffner Syndrome, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: May 31, 2016
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Methods of increasing tonic inhibition and treating secondary insomnia
    Patent number: 9339495
    Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: May 17, 2016
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During